Physician profile
Stephen Sides
NPI 1366428914
$11,451.04
in general payments reported to CMS, 2019-2025
33 companies · $856 in 2025
The $856 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $241 · 2021: $655 · 2022: $7,475 · 2023: $719 · 2024: $690 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244 · Consulting Fee: $21.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.24 |
| Consulting Fee | $21.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $6,482.97 | 2022 | |
| Amgen INC. | $1,160.91 | 2019-2025 | Enbrel, Evenity, Uplizna |
| Abbvie INC. | $979.91 | 2019-2024 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $778.47 | 2019-2025 | Tremfya, Stelara, Remicade |
| Astrazeneca Pharmaceuticals Lp | $540.21 | 2022-2025 | Saphnelo, Farxiga |
| Pfizer INC. | $399.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $290.15 | 2022-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $139.71 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $69.22 | 2022-2025 | Capvaxive, Gardasil 9 |
| Radius Health, INC. | $61.02 | 2021-2022 | |
| Dexcom, INC. | $48.48 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $38.65 | 2025 | Recorlev |
| Pharmacosmos Therapeutics INC. | $38.64 | 2024 | Monoferric |
| Lilly USA, LLC | $37.96 | 2023-2025 | Omvoh, Jardiance |
| Astellas Pharma US INC | $36.98 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $35.17 | 2023-2025 | Gemtesa |
| Daiichi Sankyo INC. | $32.50 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $28.15 | 2025 | |
| Medtronic, INC. | $26.35 | 2025 | Kyphon Express II Kyphopak Tray |
| Novartis Pharmaceuticals Corporation | $26.30 | 2020-2021 | |
| Sandoz INC. | $22.68 | 2025 | Jubbonti |
| Genentech USA, INC. | $22.12 | 2025 | Ocrevus Zunovo |
| Adma Biomanufacturing LLC | $21.36 | 2025 | |
| Biogen, INC. | $16.67 | 2021 | |
| Ucb, INC. | $16.63 | 2024 | Cimzia |
| Esperion Therapeutics, INC. | $16.61 | 2020 | |
| Sanofi Pasteur INC. | $16.16 | 2019 | |
| Averitas Pharma INC. | $14.63 | 2024 | Qutenza |
| Idorsia Pharmaceuticals US INC | $14.31 | 2022 | |
| Melinta Therapeutics, LLC | $13.81 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.26 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.26 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Sides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.